A study demonstrated that the mitochondria-targeted antioxidant catalase (MCAT) transgenic AD mice (AD-MCAT) have longer survival and lower expression of neuropathological markers of AD (APP, oligo-Aβ) than AD mice [137]. This evidence concerns the gene CAT and Alzheimer disease.